Ezetimibe/rosuvastatin - Hyundai Pharm
Alternative Names: Ezetimibe 10mg/rosuvastatin 10mg - Hyundai PharmLatest Information Update: 07 Nov 2024
Price :
$50 *
At a glance
- Originator Hyundai Pharmaceutical
- Class Antihyperlipidaemics; Azetidines; Fluorobenzenes; Phenols; Propanols; Pyrimidines; Small molecules; Sulfonamides
- Mechanism of Action Cholesterol absorption inhibitors; HMG-CoA reductase inhibitors; NPC1L1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Dyslipidaemias; Type 2 diabetes mellitus
Most Recent Events
- 07 Nov 2024 Hyundai Pharm plans a phase III trial for Hypertension and Hypercholesterolaemia (PO, Tablet) in January 2025 (NCT06646354)
- 20 Jun 2024 Phase-I clinical trials in Dyslipidaemias (In volunteers) in South Korea (PO) (NCT06578676) (700376391
- 20 Jun 2024 Phase-I clinical trials in Type 2 diabetes mellitus (In volunteers) in South Korea (PO) (NCT06578676)